肿瘤细胞治疗研究
英文原题：Spatial dissection of antibody-drug conjugate/radiopharmaceutical therapy targets defines heterogeneous expression landscapes and therapeutic implications in rhabdoid tumors.
这些发现确定了 RT 中一组具有生物学和临床相关性的表面靶点，并为儿童癌症中合理的 ADC 和 RPT 靶点开发提供了转化蓝图。
背景：横纹肌样肿瘤（RT）是侵袭性最强的儿童恶性肿瘤之一，特点为发病年龄早、SWI/SNF复合物成员（SMARCB1或SMARCA4）缺失，且尽管接受多模式治疗，结局仍极差。难治和复发RT几乎无一例外致命，靶向或免疫治疗方法尚未显示临床获益。 方法：为探索新的治疗脆弱性，我们系统研究了具有临床可靶向性的表面蛋白表达，这些蛋白可作为抗体药物偶联物（ADC）、放射性药物治疗（RPT）或细胞免疫疗法的靶点。基于大规模转录组分析，我们优先选择FAP（成纤维细胞活化蛋白）、CXCR4（趋化因子受体4）和IL13RA2（白细胞介素13受体α2），并在前所未有的60例横纹肌样肿瘤队列中，通过免疫组化进行全面蛋白水平验证，覆盖所有分子亚组（ATRT-TYR、ATRT-SHH、ATRT-MYC和eMRT）。 结果：将这些数据与空间及单核转录组分析相结合后，我们发现亚组和细胞类型特异性表达模式，包括FAP在基质和肿瘤区室之间的异质分布，以及具有黑素体和干细胞样特征的独特IL13RA2阳性横纹肌样细胞群。总体上，60例肿瘤中51例的基质FAP阳性（定义为免疫组化H评分≥10），34例CXCR4阳性，提示相当一部分横纹肌样肿瘤可能适合靶向这些表位的疗法。 结论：这些发现界定了RT中具有生物学和临床意义的一组表面靶点，并为儿科癌症中合理开发ADC和RPT靶点提供了转化研究蓝图。 通俗摘要：横纹肌样肿瘤罕见但侵袭性很强，尤其复发后生存率很低，亟需新型靶向治疗。本研究寻找肿瘤细胞表面可被现代治疗（如CAR-T细胞、抗体药物偶联物或靶向放射治疗）攻击的蛋白，发现FAP、CXCR4和IL13RA2三个有前景的靶点，并在60例儿童肿瘤样本中确认其存在。值得注意的是，IL13RA2标记了一类类似干细胞的肿瘤细胞群，可能推动治疗耐药。由于针对这些靶点的疗法已用于其他癌症，本研究结果有望加快儿童横纹肌样肿瘤新治疗方案的开发。
BACKGROUND: Rhabdoid tumors (RT) are among the most aggressive pediatric malignancies, characterized by early onset in life, loss of SWI/SNF complex members (SMARCB1 or SMARCA4), and dismal outcomes despite multimodal therapy. Refractory and relapsing RT remain almost uniformly fatal, and targeted or immune-based approaches have yet to demonstrate clinical benefit. METHODS: To explore novel therapeutic vulnerabilities, we systematically investigated the expression of clinically actionable surface proteins that could serve as targets for antibody-drug conjugates (ADCs), radiopharmaceutical therapy (RPT), or cellular immunotherapies. Based on large-scale transcriptomic analyses, we prioritized FAP (fibroblast activation protein), CXCR4 (chemokine receptor 4), and IL13RA2 (interleukin receptor 13 RA2) and performed comprehensive protein-level validation by immunohistochemistry in an unprecedented cohort of 60 rhabdoid tumors spanning all molecular subgroups (ATRT-TYR, ATRT-SHH, ATRT-MYC, and eMRT). RESULTS: Integrating these data with spatial and single-nucleus transcriptomic profiling, we identified subgroup- and cell-type-specific expression patterns, including heterogeneous FAP distribution between stromal and tumor compartments and a distinct IL13RA2-positive rhabdoid cell population with melanosomal and stem-like features: Overall 51/60 tumors demonstrated positivity, defined as immunohistochemical H-score above or at least equal to 10, for FAP in the stroma and 34/60 tumors for CXCR4, indicating that a substantial fraction of rhabdoid tumors may be amenable to targeted therapies directed against these epitopes. CONCLUSION: These findings define a set of biologically and clinically relevant surface targets in RT and provide a translational blueprint for rational ADC and RPT target development in pediatric cancer. Rhabdoid tumors are rare but highly aggressive cancers with poor survival, especially after relapse. New targeted therapies are urgently needed. In this study, we searched for proteins on tumor cells that could be attacked using modern treatments such as CAR T cells, antibody-drug conjugates, or targeted radiation therapies. We identified 3 promising targets FAP, CXCR4, and IL13RA2 and confirmed their presence in tumor samples from 60 children. Importantly, IL13RA2 marked a stem cell-like tumor population that may drive therapy resistance. Because therapies against these targets already exist for other cancers, our findings could help accelerate new treatment options for children with rhabdoid tumors.
MEMBER ACCOUNT
登录成功会直接打开下一页。
